CJC-1295 + Ipamorelin Australia

CJC-1295 + Ipamorelin Australia. This is the standard growth hormone research pairing. What it reports is a bigger growth hormone pulse and the IGF-1 rise that follows, IGF-1 being the marker that confirms the pulse was real. From there the work tracks recovery from training and injury, sleep depth, since growth hormone is released mostly during deep sleep, and the split between lean mass and fat mass.

How it does it. The pituitary gland has two separate switches for releasing growth hormone, and each peptide presses a different one. CJC-1295 is a stabilised copy of GHRH, the brain's own release signal. Ipamorelin acts on the ghrelin receptor, an independent trigger on the same cells. They are paired precisely because they are not redundant: two different receptors converging on one pathway.

The vial. Both components are independently HPLC-content-tested by Janoshik, with per peptide content reported on the certificate of analysis rather than as one combined figure. Supplied as a single vial, dispatched from Australia, AUD pricing. Supplied strictly for in-vitro and laboratory research use only. Not for human or animal consumption, not a therapeutic good, not TGA-approved.

Also written cjc 1295 ipamorelin. CJC 1295 Ipamorelin Australia, with or without the hyphen, refers to this same co-lyophilised vial: CJC-1295 (no DAC), the growth-hormone-releasing-hormone analogue, paired with Ipamorelin, the selective ghrelin-receptor agonist.

The blend is a formulation rather than a single chemical entity, so it carries no single CAS number or molecular weight — each component has its own identity. CJC-1295 (no DAC), also catalogued as Mod GRF (1-29), is a 30-residue stabilised GHRH(1-29) analogue; Ipamorelin is a synthetic pentapeptide and a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a).

Ipamorelin was characterised by Raun and colleagues (European Journal of Endocrinology, 1998) as the first selective growth-hormone secretagogue, acting on the GHS-R1a receptor cloned by Howard and colleagues (Science, 1996). The stabilising D-Ala2 substitution central to the Mod GRF (1-29) / no-DAC GHRH backbone was characterised by Soule and colleagues (The Journal of Clinical Endocrinology & Metabolism, 1994).

The pairing is referenced across growth-hormone-secretagogue research literature because GHRH analogues and GHRPs act on distinct receptors with downstream convergence at the somatotrophic axis. Researchers typically reference the literature for each peptide separately — the receptor-binding profile of the GHRH analogue and the selectivity profile of the GHRP — and use the co-lyophilised vial as a methodological convenience.

See the CJC-1295 (no DAC) and Ipamorelin standalone product pages for the individual compounds and their full identity data.

The information provided here is a research-reference summary only. Elite AU Peptides makes no medical, therapeutic, performance, or human-use claim about this product or its components. Both components are supplied strictly for in-vitro and laboratory research use only — not therapeutic goods, not TGA-approved.

Reconstitute the co-lyophilised vial with bacteriostatic water for laboratory handling. Add the diluent slowly down the vial wall and swirl gently rather than shaking. Typical research protocols target a per-component working concentration based on the protocol’s downstream assay requirements; the per-peptide content reported on the certificate of analysis is the canonical reference for the concentration math.

Store the lyophilised powder at −20°C, desiccated and protected from light; once reconstituted, store refrigerated at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles. Tamper-evident packaging; the batch label is the canonical reference for the certificate of analysis published in the lab-reports library.

Shop bacteriostatic water

Australia only. Free shipping over $100. Orders placed before 12pm AEST are dispatched the same business day from Australia.

30-day returns on unused product in original packaging, with prior approval.